{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T07:07:08Z","timestamp":1790665628722,"version":"4.1.0"},"reference-count":51,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,5]],"date-time":"2022-08-05T00:00:00Z","timestamp":1659657600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.cllc.2022.07.017","type":"journal-article","created":{"date-parts":[[2022,8,10]],"date-time":"2022-08-10T15:17:59Z","timestamp":1660144679000},"page":"e526-e535","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["Cardiopulmonary Toxicity Following Intensity-Modulated Proton Therapy (IMPT) Versus Intensity-Modulated Radiation Therapy (IMRT) for Stage III Non-Small Cell Lung Cancer"],"prefix":"10.1016","volume":"23","author":[{"given":"Nathan Y.","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd A.","family":"DeWees","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Molly M.","family":"Voss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William G.","family":"Breen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer S.","family":"Chiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia X.","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas B.","family":"Daniels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawn","family":"Owen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth R.","family":"Olivier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yolanda I.","family":"Garces","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean S.","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jann N.","family":"Sarkaria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panayiotis S.","family":"Savvides","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinicius","family":"Ernani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven E.","family":"Schild","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth W.","family":"Merrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terence T.","family":"Sio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cllc.2022.07.017_bib0001","first-page":"7","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.cllc.2022.07.017_bib0002","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/S0025-6196(11)60735-0","article-title":"Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship","volume":"83","author":"Molina","year":"2008","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.cllc.2022.07.017_bib0003","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1097\/JTO.0b013e318180270b","article-title":"Locally advanced non-small cell lung cancer: the past, present, and future","volume":"3","author":"Govindan","year":"2008","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.cllc.2022.07.017_bib0004","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.1200\/JCO.1999.17.9.2692","article-title":"Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer","volume":"17","author":"Furuse","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2022.07.017_bib0005","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1093\/jnci\/djr325","article-title":"Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410","volume":"103","author":"Curran","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.cllc.2022.07.017_bib0006","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1200\/JCO.2009.26.2543","article-title":"Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer","volume":"28","author":"Aup\u00e9rin","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2022.07.017_bib0007","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa1809697","article-title":"Overall Survival with Durvalumab after Chemoradiotherapy in stage III NSCLC","volume":"379","author":"Antonia","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cllc.2022.07.017_bib0008","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.lungcan.2015.01.006","article-title":"Cardiovascular comorbidities and survival of lung cancer patients: Medicare data based analysis","volume":"88","author":"Kravchenko","year":"2015","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2022.07.017_bib0009","first-page":"144","article-title":"Predictive factors for survival and correlation to toxicity in advanced Stage III non-small cell lung cancer patients with concurrent chemoradiation","volume":"46","author":"Kim","year":"2016","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.cllc.2022.07.017_bib0010","doi-asserted-by":"crossref","first-page":"3201","DOI":"10.1200\/JCO.2003.12.019","article-title":"The outcome of combined-modality therapy for stage III non-small-cell lung cancer in the elderly","volume":"21","author":"Schild","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2022.07.017_bib0011","doi-asserted-by":"crossref","first-page":"2885","DOI":"10.1200\/JCO.2016.71.4758","article-title":"Pooled analysis of individual patient data on concurrent chemoradiotherapy for stage III non-small-cell lung cancer in elderly patients compared with younger patients who participated in US national cancer institute cooperative group studies","volume":"35","author":"Stinchcombe","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2022.07.017_bib0012","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S1470-2045(14)71207-0","volume":"16","author":"Bradley","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cllc.2022.07.017_bib0013","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1200\/JCO.2016.69.1378","article-title":"Impact of intensity-modulated radiation therapy technique for locally advanced non-small-cell lung cancer: a secondary analysis of the NRG oncology RTOG 0617 randomized clinical trial","volume":"35","author":"Chun","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2022.07.017_bib0014","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ijrobp.2016.10.001","article-title":"National cancer database analysis of proton versus photon radiation therapy in non-small cell lung cancer","volume":"97","author":"Higgins","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.cllc.2022.07.017_bib0015","doi-asserted-by":"crossref","first-page":"3004","DOI":"10.1002\/cncr.25848","article-title":"Early findings on toxicity of proton beam therapy with concurrent chemotherapy for non small cell lung cancer","volume":"117","author":"Sejpal","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.cllc.2022.07.017_bib0016","doi-asserted-by":"crossref","first-page":"e620","DOI":"10.1016\/S1470-2045(14)70345-6","article-title":"High-dose re-irradiation following radical radiotherapy for non-small-cell lung cancer","volume":"15","author":"De Ruysscher","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cllc.2022.07.017_bib0017","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.ijrobp.2006.01.052","article-title":"Significant reduction of normal tissue dose by proton radiotherapy compared with three-dimensional conformal or intensity-modulated radiation therapy in stage I or stage III non-small-cell lung cancer","volume":"65","author":"Chang","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.cllc.2022.07.017_bib0018","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1002\/acm2.12459","article-title":"Small-spot intensity-modulated proton therapy and volumetric-modulated arc therapies for patients with locally advanced non-small-cell lung cancer: A dosimetric comparative study","volume":"19","author":"Liu","year":"2018","journal-title":"J Appl Clin Med Phys"},{"key":"10.1016\/j.cllc.2022.07.017_bib0019","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1080\/02841860500361049","article-title":"Number of patients potentially eligible for proton therapy","volume":"44","author":"Glimelius","year":"2005","journal-title":"Acta Oncol Stockh Swed"},{"key":"10.1016\/j.cllc.2022.07.017_bib0020","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.ijrobp.2018.02.009","article-title":"Impact of spot size and spacing on the quality of robustly-optimized intensity-modulated proton therapy plans for lung cancer","volume":"101","author":"Liu","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.cllc.2022.07.017_bib0021","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.ijrobp.2015.11.002","article-title":"Exploratory study of 4D versus 3D robust optimization in intensity modulated proton therapy for lung cancer","volume":"95","author":"Liu","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.cllc.2022.07.017_bib0022","doi-asserted-by":"crossref","DOI":"10.1002\/mp.13809","article-title":"Technical Note: Treatment Planning System (TPS) Approximations Matter-Comparing Intensity Modulated Proton Therapy (IMPT) Plan Quality and Robustness between a Commercial and an In-house Developed TPS for Non-Small Cell Lung Cancer (NSCLC)","author":"Liu","year":"2019","journal-title":"Med Phys"},{"key":"10.1016\/j.cllc.2022.07.017_bib0023","doi-asserted-by":"crossref","DOI":"10.1118\/1.4815798","article-title":"Effectiveness of robust optimization in intensity-modulated proton therapy planning for head and neck cancers","volume":"40","author":"Liu","year":"2013","journal-title":"Med Phys"},{"key":"10.1016\/j.cllc.2022.07.017_bib0024","article-title":"PTV-based IMPT optimization incorporating planning risk volumes vs. robust optimization","volume":"40","author":"Liu","year":"2013","journal-title":"Med Phys"},{"key":"10.1016\/j.cllc.2022.07.017_bib0025","doi-asserted-by":"crossref","first-page":"3089","DOI":"10.1118\/1.4711909","article-title":"Influence of robust optimization in intensity-modulated proton therapy with different dose delivery techniques","volume":"39","author":"Liu","year":"2012","journal-title":"Med Phys"},{"key":"10.1016\/j.cllc.2022.07.017_bib0026","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.prro.2013.12.001","article-title":"Dosimetric benefits of robust treatment planning for intensity modulated proton therapy for base-of-skull cancers","volume":"4","author":"Liu","year":"2014","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.cllc.2022.07.017_bib0027","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1118\/1.3679340","article-title":"Robust optimization of intensity modulated proton therapy","volume":"39","author":"Liu","year":"2012","journal-title":"Med Phys"},{"key":"10.1016\/j.cllc.2022.07.017_bib0028","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1002\/acm2.12459","article-title":"Small-spot intensity-modulated proton therapy and volumetric-modulated arc therapies for patients with locally advanced non-small-cell lung cancer: A dosimetric comparative study","volume":"19","author":"Liu","year":"2018","journal-title":"J Appl Clin Med Phys"},{"key":"10.1016\/j.cllc.2022.07.017_bib0029","doi-asserted-by":"crossref","first-page":"e77","DOI":"10.1016\/j.prro.2014.08.002","article-title":"Impact of respiratory motion on worst-case scenario optimized intensity modulated proton therapy for lung cancers","volume":"5","author":"Liu","year":"2015","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.cllc.2022.07.017_bib0030","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.ijrobp.2015.11.002","article-title":"Exploratory study of 4D versus 3D robust optimization in intensity modulated proton therapy for lung cancer","volume":"95","author":"Liu","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.cllc.2022.07.017_bib0031","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/mp.12001","article-title":"Robust treatment planning with conditional value at risk chance constraints in intensity-modulated proton therapy","volume":"44","author":"An","year":"2017","journal-title":"Med Phys"},{"key":"10.1016\/j.cllc.2022.07.017_bib0032","doi-asserted-by":"crossref","first-page":"6138","DOI":"10.1002\/mp.12610","article-title":"Robust intensity-modulated proton therapy to reduce high linear energy transfer in organs at risk","volume":"44","author":"An","year":"2017","journal-title":"Med Phys"},{"key":"10.1016\/j.cllc.2022.07.017_bib0033","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1002\/mp.12677","article-title":"Robust optimization in IMPT using quadratic objective functions to account for the minimum MU constraint","volume":"45","author":"Shan","year":"2018","journal-title":"Med Phys"},{"key":"10.1016\/j.cllc.2022.07.017_bib0034","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1002\/mp.13276","article-title":"A novel and individualized robust optimization method using normalized dose interval volume constraints (NDIVC) for intensity-modulated proton radiotherapy","volume":"46","author":"Shan","year":"2019","journal-title":"Med Phys"},{"key":"10.1016\/j.cllc.2022.07.017_bib0035","doi-asserted-by":"crossref","DOI":"10.1002\/mp.14491","article-title":"Intensity-modulated proton therapy (IMPT) interplay effect evaluation of asymmetric breathing with simultaneous uncertainty considerations in patients with non-small-cell lung cancer","author":"Shan","year":"2020","journal-title":"Med Phys"},{"key":"10.1016\/j.cllc.2022.07.017_bib0036","doi-asserted-by":"crossref","first-page":"4636","DOI":"10.1002\/mp.15003","article-title":"Technical Note: 4D robust optimization in small spot intensity-modulated proton therapy (IMPT) for distal esophageal carcinoma","volume":"48","author":"Feng","year":"2021","journal-title":"Med Phys"},{"key":"10.1016\/j.cllc.2022.07.017_bib0037","doi-asserted-by":"crossref","DOI":"10.1002\/mp.15056","article-title":"Technical Note: Multiple energy extraction techniques for synchrotron-based proton delivery systems may exacerbate motion interplay effects in lung cancer treatments","author":"Younkin","year":"2021","journal-title":"Med Phys"},{"key":"10.1016\/j.cllc.2022.07.017_bib0038","article-title":"The impact of variable RBE in proton therapy for left-sided breast cancer when estimating normal tissue complications in the heart and lung [published online ahead of print 2020\/12\/10]","author":"Marteinsdottir","year":"2020","journal-title":"Phys Med Biol"},{"key":"10.1016\/j.cllc.2022.07.017_bib0039","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.ijrobp.2021.02.024","article-title":"Exploratory Investigation of Dose-Linear Energy Transfer (LET) Volume Histogram (DLVH) for Adverse Events Study in Intensity Modulated Proton Therapy (IMPT) [published online ahead of print 2021\/02\/24]","volume":"110","author":"Yang","year":"2021","journal-title":"Intel J Rad Oncol"},{"key":"10.1016\/j.cllc.2022.07.017_bib0040","doi-asserted-by":"crossref","DOI":"10.1177\/1533033819887182","article-title":"Clinical validation of a ray-casting analytical dose engine for spot scanning proton delivery systems","volume":"18","author":"Younkin","year":"2019","journal-title":"Technol Cancer Res Treat"},{"key":"10.1016\/j.cllc.2022.07.017_bib0041","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1002\/mp.13934","article-title":"Hybrid 3D analytical linear energy transfer calculation algorithm based on precalculated data from Monte Carlo simulations","volume":"47","author":"Deng","year":"2020","journal-title":"Med Phys"},{"key":"10.1016\/j.cllc.2022.07.017_bib0042","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1002\/mp.14125","article-title":"Technical Note: Integrating an open source Monte Carlo code \"MCsquare\" for clinical use in intensity-modulated proton therapy","volume":"47","author":"Deng","year":"2020","journal-title":"Med Phys"},{"key":"10.1016\/j.cllc.2022.07.017_bib0043","unstructured":"Deng W, Yang Y, Liu C, et\u00a0al. A critical review of LET-based intensity-modulated proton therapy (IMPT) plan evaluation and optimization for head and neck cancer management, accepted by IJPT 2020"},{"key":"10.1016\/j.cllc.2022.07.017_bib0044","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.ijrobp.2006.01.052","article-title":"Significant reduction of normal tissue dose by proton radiotherapy compared with three-dimensional conformal or intensity-modulated radiation therapy in stage I or stage III non-small-cell lung cancer","volume":"65","author":"Chang","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.cllc.2022.07.017_bib0045","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1200\/JCO.2017.74.0720","article-title":"Bayesian Adaptive Randomization Trial of Passive Scattering Proton Therapy and Intensity-Modulated Photon Radiotherapy for Locally Advanced Non-Small-Cell Lung Cancer [published correction appears in J Clin Oncol. 2018 Aug 20;36(24):2570]","volume":"36","author":"Liao","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2022.07.017_bib0046","first-page":"30839","article-title":"Toxicity and Survival after Intensity-Modulated Proton Therapy (IMPT) versus Passive Scattering Proton Therapy (PSPT) for Non-Small Cell Lung Cancer","volume":"S1556-0864","author":"Gjyshi","year":"2020","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.cllc.2022.07.017_bib0047","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.radonc.2015.05.014","article-title":"Long-term outcomes after proton therapy, with concurrent chemotherapy, for stage II-III inoperable non-small cell lung cancer","volume":"115","author":"Nguyen","year":"2015","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.cllc.2022.07.017_bib0048","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2017.2032","article-title":"Proton beam radiotherapy and concurrent chemotherapy for unresectable stage iii non-small cell lung cancer: final results of a phase 2 study","volume":"3","author":"Chang","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.cllc.2022.07.017_bib0049","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s10147-014-0679-1","article-title":"Radiotherapy for thoracic tumors: association between subclinical interstitial lung disease and fatal radiation pneumonitis","volume":"20","author":"Yamaguchi","year":"2015","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.cllc.2022.07.017_bib0050","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.lungcan.2013.08.024","article-title":"Stereotactic body radiotherapy for lung tumors in patients with subclinical interstitial lung disease: the potential risk of extensive radiation pneumonitis","volume":"82","author":"Yamaguchi","year":"2013","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2022.07.017_bib0051","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s13014-016-0640-8","article-title":"Establishing the feasibility of the dosimetric compliance criteria of RTOG 1308: phase III randomized trial comparing overall survival after photon versus proton radiochemotherapy for inoperable stage II-IIIB NSCLC","volume":"11","author":"Giaddui","year":"2016","journal-title":"Radiat Oncol"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152573042200170X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152573042200170X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T19:13:15Z","timestamp":1761505995000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S152573042200170X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":51,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["S152573042200170X"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2022.07.017","relation":{},"ISSN":["1525-7304"],"issn-type":[{"value":"1525-7304","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardiopulmonary Toxicity Following Intensity-Modulated Proton Therapy (IMPT) Versus Intensity-Modulated Radiation Therapy (IMRT) for Stage III Non-Small Cell Lung Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2022.07.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}